$ARTL
ARTELO BIOSCIENCES, INC.

2022 Q4 Form 10-Q Financial Statement

#000164033422002363 Filed on November 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.750M $1.316M $1.279M
YoY Change 36.83% 3.51% 52.26%
% of Gross Profit
Research & Development $1.726M $1.078M $1.273M
YoY Change 35.59% 75.15% 113.95%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.476M $2.394M $2.552M
YoY Change 36.21% 26.88% 77.72%
Operating Profit -$2.394M -$2.552M
YoY Change 6.64% 77.72%
Interest Expense $137.0K $5.000K $3.000K
YoY Change 4466.67% -1662.5%
% of Operating Profit
Other Income/Expense, Net $64.00K $4.000K
YoY Change 11751.85% 300.0%
Pretax Income -$3.339M -$2.330M -$2.548M
YoY Change 31.04% 23.5% 78.18%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.339M -$2.330M -$2.548M
YoY Change 31.04% 23.5% 77.56%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.18 -$817.8K -$1.255M
COMMON SHARES
Basic Shares Outstanding 2.856M shares 42.59M shares 42.30M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.383M $8.624M $24.11M
YoY Change -65.23% -14.32% 226.29%
Cash & Equivalents $6.888M $7.136M $12.16M
Short-Term Investments $1.495M $1.488M $11.95M
Other Short-Term Assets $789.0K $820.0K $514.0K
YoY Change 53.5% 225.4% 367.27%
Inventory
Prepaid Expenses $789.0K $686.0K $496.0K
Receivables
Other Receivables
Total Short-Term Assets $18.32M $20.30M $24.61M
YoY Change -25.55% 96.79% 228.12%
LONG-TERM ASSETS
Property, Plant & Equipment $60.00K $70.00K $83.00K
YoY Change -27.71% -22.22% 44764.86%
Goodwill
YoY Change
Intangibles $2.039M $2.039M $2.039M
YoY Change 0.0% 0.0%
Long-Term Investments $0.00 $0.00 $1.524M
YoY Change -100.0%
Other Assets $3.000K $3.000K $3.000K
YoY Change 0.0% -98.41%
Total Long-Term Assets $2.102M $2.112M $3.642M
YoY Change -42.28% -8.89% 78.53%
TOTAL ASSETS
Total Short-Term Assets $18.32M $20.30M $24.61M
Total Long-Term Assets $2.102M $2.112M $3.642M
Total Assets $20.42M $22.42M $28.25M
YoY Change -27.71% 77.4% 196.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $905.0K $411.0K $590.0K
YoY Change 53.39% -16.63% 25.53%
Accrued Expenses $40.00K $42.00K $31.00K
YoY Change 29.03% 50.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $998.0K $480.0K $1.027M
YoY Change -2.82% -8.75% 109.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $23.00K $32.00K $59.00K
YoY Change -61.02% -52.24%
Total Long-Term Liabilities $23.00K $32.00K $59.00K
YoY Change -61.02% -52.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $998.0K $480.0K $1.027M
Total Long-Term Liabilities $23.00K $32.00K $59.00K
Total Liabilities $1.021M $512.0K $1.084M
YoY Change -5.81% -13.66% 121.22%
SHAREHOLDERS EQUITY
Retained Earnings -$31.02M -$27.68M -$20.94M
YoY Change 48.16% 63.77%
Common Stock $3.000K $3.000K $42.00K
YoY Change -92.86% -88.0% 177.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $19.40M $21.90M $27.17M
YoY Change
Total Liabilities & Shareholders Equity $20.42M $22.42M $28.25M
YoY Change -27.71% 77.4% 196.13%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q4
OPERATING ACTIVITIES
Net Income -$3.339M -$2.330M -$2.548M
YoY Change 31.04% 23.5% 77.56%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.293M -$1.696M -$1.926M
YoY Change 19.06% 10.04% 45.91%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $1.796M -$3.080M -$8.878M
YoY Change -120.23% -10.44%
Cash From Investing Activities $1.796M -$3.080M -$8.878M
YoY Change -120.23% -10.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $18.26M
YoY Change 177.58%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 134.0K 0.000 $18.26M
YoY Change -99.27% -100.0% 177.58%
NET CHANGE
Cash From Operating Activities -2.293M -1.696M -$1.926M
Cash From Investing Activities 1.796M -3.080M -$8.878M
Cash From Financing Activities 134.0K 0.000 $18.26M
Net Change In Cash -363.0K -4.776M $7.458M
YoY Change -104.87% 41.15% 41.81%
FREE CASH FLOW
Cash From Operating Activities -$2.293M -$1.696M -$1.926M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
0 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
1524000 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
416667 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2855688 shares
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
18262 usd
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
20000 usd
artl Weighted Average Number Of Diluted Instruments
WeightedAverageNumberOfDilutedInstruments
583162 shares
artl Weighted Average Number Of Diluted Instruments
WeightedAverageNumberOfDilutedInstruments
486214 shares
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
7136 usd
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
12162 usd
CY2022Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2022Q3 artl Amount In Excess Of Fdic Insurance Amount
AmountInExcessOfFdicInsuranceAmount
6600 usd
CY2021Q4 artl Available For Sale Security
AvailableForSaleSecurity
1519 usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.89
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
416667 shares
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
134 usd
CY2022Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
2356000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
313109 shares
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
333945 shares
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
24.45
artl Weighted Average Remaining Contractual Life In Years Beginning
WeightedAverageRemainingContractualLifeInYearsBeginning
P9Y4M9D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y1M20D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
24838 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
25.69
artl Weighted Average Remaining Contractual Life In Years Forfeitures And Expirations
WeightedAverageRemainingContractualLifeInYearsForfeituresAndExpirations
P8Y8M26D
artl Weighted Average Remaining Contractual Life In Years Ending
WeightedAverageRemainingContractualLifeInYearsEnding
P8Y7M28D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
90315 shares
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
624000 usd
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
416667 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
dei Entity Central Index Key
EntityCentralIndexKey
0001621221
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2855688 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2820068 shares
CY2021Q4 artl Trading Marketable Securities Corporate Debt Securities
TradingMarketableSecuritiesCorporateDebtSecurities
300000 usd
CY2022Q2 artl Total Available For Sale Securities
TotalAvailableForSaleSecurities
1488 usd
CY2021Q4 artl Intangible Asset
IntangibleAsset
2000000.0 usd
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2859184 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38951
dei Entity Registrant Name
EntityRegistrantName
ARTELO BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-1220924
dei Entity Address Address Line1
EntityAddressAddressLine1
505 Lomas Santa Fe
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 160
dei Entity Address City Or Town
EntityAddressCityOrTown
Solana Beach
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
925-7049
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
ARTL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Address Country
EntityAddressCountry
US
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92075
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2855688 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7136000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12162000 usd
CY2022Q3 us-gaap Marketable Securities
MarketableSecurities
10859000 usd
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
11951000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
1524000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1488000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0 usd
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
686000 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
496000 usd
CY2022Q3 artl Deferred Cost
DeferredCost
134000 usd
CY2021Q4 artl Deferred Cost
DeferredCost
0 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
20303000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
24609000 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2039000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2039000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
0 usd
CY2022Q3 artl Available For Sale Securities Non Current
AvailableForSaleSecuritiesNonCurrent
0 usd
CY2021Q4 artl Available For Sale Securities Non Current
AvailableForSaleSecuritiesNonCurrent
1519000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
70000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
81000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3000 usd
CY2022Q3 us-gaap Assets
Assets
22415000 usd
CY2021Q4 us-gaap Assets
Assets
28251000 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
411000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
975000 usd
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
27000 usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
21000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
42000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
31000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
480000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1027000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
57000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
512000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
1084000 usd
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2820068 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
49970000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
48120000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-27682000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20938000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-388000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-18000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
21903000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
27167000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22415000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28251000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1316000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1211000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4213000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3884000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1078000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1034000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2598000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2311000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
2394000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
2245000 usd
us-gaap Operating Expenses
OperatingExpenses
6811000 usd
us-gaap Operating Expenses
OperatingExpenses
6195000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2394000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2245000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6811000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6195000 usd
CY2022Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
0 usd
CY2021Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
0 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
2000 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
1000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
5000 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
0 usd
us-gaap Interest Expense
InterestExpense
5000 usd
us-gaap Interest Expense
InterestExpense
0 usd
CY2022Q3 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
69000 usd
CY2021Q3 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
0 usd
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
70000 usd
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
2000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
64000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
67000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2330000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-2245000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6744000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6192000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
2000 usd
CY2021Q3 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
0 usd
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
31000 usd
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
0 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-210000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-339000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-28000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-212000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-12000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-370000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-28000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2542000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2257000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7114000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6220000 usd
CY2022Q3 artl Earnings Per Share Basics And Diluted
EarningsPerShareBasicsAndDiluted
-0.82
CY2021Q3 artl Earnings Per Share Basics And Diluted
EarningsPerShareBasicsAndDiluted
-1.37
artl Earnings Per Share Basics And Diluted
EarningsPerShareBasicsAndDiluted
-2.38
artl Earnings Per Share Basics And Diluted
EarningsPerShareBasicsAndDiluted
-3.97
CY2022Q3 artl Weighted Average Number Of Share Outstanding Basics And Diluted
WeightedAverageNumberOfShareOutstandingBasicsAndDiluted
2849000 shares
CY2021Q3 artl Weighted Average Number Of Share Outstanding Basics And Diluted
WeightedAverageNumberOfShareOutstandingBasicsAndDiluted
1635000 shares
artl Weighted Average Number Of Share Outstanding Basics And Diluted
WeightedAverageNumberOfShareOutstandingBasicsAndDiluted
2833000 shares
artl Weighted Average Number Of Share Outstanding Basics And Diluted
WeightedAverageNumberOfShareOutstandingBasicsAndDiluted
1561000 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
27167000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1965000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
25780000 usd
CY2022Q2 artl Common Shares Issued For Commitment Fee Amount
CommonSharesIssuedForCommitmentFeeAmount
0 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
619000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2449000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-112000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
23838000 usd
CY2022Q3 artl Stock Issued During Period Shares Value Reverse Stock Splits
StockIssuedDuringPeriodSharesValueReverseStockSplits
0 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
607000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2330000 usd
CY2022Q3 artl Comprehensive Income Net Of Tax1
ComprehensiveIncomeNetOfTax1
-212000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
21903000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
8435000 usd
CY2021Q1 artl Common Shares Issued For Exercise Of Warrant Amount
CommonSharesIssuedForExerciseOfWarrantAmount
6016000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
11000 usd
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
519000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-1695000 usd
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
13288000 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1204000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
7000 usd
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
609000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2252000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-18000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
12838000 usd
CY2021Q3 artl Common Stock Shares Issued Value For Cash
CommonStockSharesIssuedValueForCash
397000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
3000 usd
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
502000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-2245000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-12000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
11483000 usd
us-gaap Profit Loss
ProfitLoss
6744000 usd
us-gaap Profit Loss
ProfitLoss
6192000 usd
artl Stock Based Compensation
StockBasedCompensation
1850000 usd
artl Stock Based Compensation
StockBasedCompensation
1651000 usd
artl Net Change In Fair Value Of Marketable Securities
NetChangeInFairValueOfMarketableSecurities
70000 usd
artl Net Change In Fair Value Of Marketable Securities
NetChangeInFairValueOfMarketableSecurities
2000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
28000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
10000 usd
artl Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
191000 usd
artl Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
-17000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-562000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-342000 usd
artl Increase Decrease In Account Payable
IncreaseDecreaseInAccountPayable
6000 usd
artl Increase Decrease In Account Payable
IncreaseDecreaseInAccountPayable
5000 usd
artl Increase Decrease In Fixed Cash Payments Related To Operating Leases
IncreaseDecreaseInFixedCashPaymentsRelatedToOperatingLeases
32000 usd
artl Increase Decrease In Fixed Cash Payments Related To Operating Leases
IncreaseDecreaseInFixedCashPaymentsRelatedToOperatingLeases
2000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5715000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4855000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
10542000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5029000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
499000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
11678000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3100000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
525000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1162000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1929000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1601000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
134000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6016000 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
7000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-134000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7610000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-339000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-23000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5026000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
803000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12162000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5783000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7136000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6586000 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
artl Initial Recognition Of The Right Of Use Asset
InitialRecognitionOfTheRightOfUseAsset
20000 usd
artl Initial Recognition Of The Right Of Use Asset
InitialRecognitionOfTheRightOfUseAsset
97000 usd
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
31000 usd
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
0 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ARTELO BIOSCIENCES, INC. (“we”, “us”, “our”, the “Company”) is a Nevada corporation. The Company was incorporated on May 2, 2011, and is currently based in San Diego County, California. The accounting and reporting policies of the Company conform to generally accepted accounting principles in the United States of America (“GAAP”), and the Company’s fiscal year end is December 31.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company registered wholly-owned subsidiaries in Ireland, Trinity Reliant Ventures Limited, on November 11, 2016, and in the UK, Trinity Research &amp; Development Limited, on June 2, 2017. On January 8, 2020, Trinity Research and Development Limited changed its name to Artelo Biosciences Limited. The Company incorporated a wholly-owned subsidiary in Canada, Artelo Biosciences Corporation, on March 18, 2020. Operations in the subsidiaries have been consolidated in the financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (the “ECS”), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>COVID-19</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As the COVID-19 pandemic is still evolving at this time and much of its impact remains unknown, the Company is not able to predict the impact it may have on the development of its product candidates and business. The severity of the COVID-19 pandemic could also negatively impact the Company’s access to its existing supply chain by delaying the delivery of key raw materials used in its product candidates and therefore delay the delivery of such products for use in its clinical trials. Any of these results could have a material adverse impact to our business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Liquidity</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has incurred losses since inception and a net loss of $6,744 during the nine months ended September 30, 2022. However, in November 2021, the Company completed an equity offering which generated net proceeds of $18,262. Consequently, the Company’s existing cash resources and the cash received from the equity offering are expected to provide sufficient funds to carry out the Company’s planned operations through the first half of 2024. Additionally, in May 2022, the Company entered into a purchase agreement and a registration rights agreement (the “Equity Line”) with an institutional investor, providing for the sale of up to $20,000 worth of the Company’s common stock, over the thirty-six (36) month term of the purchase agreement. Under the terms and subject to the conditions of the purchase agreement, the Company has the right, but not the obligation, to sell to the institutional investor, and the institutional investor is obligated to purchase, up to $20,000 worth of shares of the Company’s Common Stock. As of September 30, 2022, there have been no sales under the Equity Line.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Reverse stock split</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 8, 2022, the Company, filed with the Secretary of State of the State of Nevada a Certificate of Change, pursuant to Nevada Revised Statutes 78.209, to effect a one-for-fifteen (1-for-15) reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding Common Stock, par value $0.001 per share. The Reverse Split was effective as of August 10, 2022. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As a result of the Reverse Split, the number of authorized shares of Common Stock has been reduced from 750,000,000 to 50,000,000, while the number of authorized shares of the Company’s preferred stock has been reduced from 6,250,000 to 416,667.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All share and per share information in these financial statements retroactively reflect this Reverse Stock Split.</p>
artl Net Income Loss1
NetIncomeLoss1
-6744 usd
CY2022Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
20000 usd
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-15
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
6250000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
416667 shares
CY2022Q3 artl Marketable Securities1
MarketableSecurities1
10859 usd
CY2021Q4 artl Marketable Securities1
MarketableSecurities1
11951 usd
CY2022Q3 artl Available For Sale Security
AvailableForSaleSecurity
1488 usd
CY2022Q2 us-gaap Marketable Securities
MarketableSecurities
10859000 usd
CY2022Q2 artl Trading Marketable Securities Commercial Paper
TradingMarketableSecuritiesCommercialPaper
10859000 usd
CY2022Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
1488000 usd
CY2022Q2 artl Total Marketable Securities
TotalMarketableSecurities
12347 usd
CY2021Q4 artl Trading Marketable Securities Commercial Paper
TradingMarketableSecuritiesCommercialPaper
10486000 usd
CY2021Q4 artl Trading Marketable Securities Asset Backed Securities
TradingMarketableSecuritiesAssetBackedSecurities
1165000 usd
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
11951000 usd
CY2021Q4 artl Total Available For Sale Securities
TotalAvailableForSaleSecurities
1519 usd
CY2021Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
1519000 usd
CY2021Q4 artl Total Marketable Securities
TotalMarketableSecurities
13470 usd
CY2022Q3 artl Intangible Asset
IntangibleAsset
2039 usd
artl Share Based Compensations
ShareBasedCompensations
1668 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4002 shares
artl Weighted Average Remaining Contractual Life In Years Granted
WeightedAverageRemainingContractualLifeInYearsGranted
P10Y
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
313109 shares
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
24.15
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
37.71
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
On April 19, 2022, the Company entered into a lease arrangement for office space with an annual rent of $13 (£11) and the term from April 2022 through September 2023.

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001640334-22-002363-index-headers.html Edgar Link pending
0001640334-22-002363-index.html Edgar Link pending
0001640334-22-002363.txt Edgar Link pending
0001640334-22-002363-xbrl.zip Edgar Link pending
artl-20220930.xsd Edgar Link pending
artl_10q.htm Edgar Link pending
artl_ex211.htm Edgar Link pending
artl_ex311.htm Edgar Link pending
artl_ex321.htm Edgar Link pending
artl-20220930_cal.xml Edgar Link unprocessable
artl-20220930_def.xml Edgar Link unprocessable
artl-20220930_lab.xml Edgar Link unprocessable
artl-20220930_pre.xml Edgar Link unprocessable
artl_10q_htm.xml Edgar Link completed
artl_ex33.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending